Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | OGG1 | O15527 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348299 | 0.89 | HSD17B10 (0.36) | CA1CA2ALOX15HDAC1HDAC8 | |
| SCHEMBL6962236 | 0.80 | OGG1 (0.56) | CES2CES1OGG1CA1CA2 | |
| SCHEMBL15382959 | 0.80 | CES2 (0.42) | CES2CES1OGG1CA1CA2 | |
| SCHEMBL20428680 | 0.80 | CES2 (0.42) | CES2CES1OGG1CA1CA2 | |
| SCHEMBL771387 | 0.79 | LMNA (0.50) | CA1CA2ALOX15NPC1RAB9A | |
| SCHEMBL2100964 | 0.78 | CYP2A6 (0.45) | CYP2A6NPC1RAB9A | |
| SCHEMBL4619841 | 0.77 | PLAU (0.54) | CA1CA2ALOX15HDAC1HDAC8 | |
| SCHEMBL193570 | 0.77 | CES2 (0.44) | CES2CES1CA1CA2HDAC1 | |
| SCHEMBL5900818 | 0.77 | PRMT5 (0.30) | — | |
| SCHEMBL641475 | 0.77 | LMNA (0.50) | CES2CES1CA1CA2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4291183-B1 | OXADIAZOLYL DIHYDROPYRANO[2,3-B]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025151705-A1 | NOVEL INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250179084-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | disclosed |
| WO-2005040144-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2005-03-31 | — | — | US | disclosed |
| WO-2005014571-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| EP-1409489-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003000694-A1 | 6-PHENYLDIHYDROPYRROLOPYRIMIDINEDIONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2003-01-03 | — | — | WO | disclosed |
| EP-0637304-A1 | 1-PIPERAZINEACETIC DERIVATIVES AS FIBRINOGEN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1995-02-08 | — | — | EP | disclosed |
| WO-1993022303-A1 | 1-PIPERAZINEACETIC DERIVATIVES AS FIBRINOGEN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | CES2 3601/4885CES1 2599/4885OGG1 107/4885 |
| US-20050070558-A1 | 6-Phenyldihydropyrrolopyrimidinedione derivatives | ADORA1, ADORA2A, P2RY10 | CES2 2932/4885CES1 943/4885OGG1 2916/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CES2 1154/4885CES1 63/4885OGG1 39/4885 |
| US-20250179084-A1 | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | HIPK2, HIPK3, HIPK1 | CES2 4857/4885CES1 4632/4885OGG1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.